Abstract
Thirty years ago, our forerunners spent thousands of hours aiming to realize antibody treatments. Would they ever have been able to imagine the advances in antibody treatments that we see today? Currently, antibody drugs cover not only malignant neoplasms but also autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus; allergic diseases such as bronchial asthma; inflammatory bowel diseases (IBD); neurological diseases; and osteoporosis: their effectiveness in these disorders have been investigated and reported. In this review, we will review the advances particularly in those against malignancies. We will also allude to their position in the treatments of RA and IBD, where now these drugs are the mainstays, and also to individual agents.
